Interactive Features

Quiz

Quiz: Treatment-Related Adverse Events in Patients with NSCLC Treated With Tiragolumab Plus Atezolizumab

09/08/2022

What did the phase 2 CITYSCAPE trial find to be the most common treatment-related adverse event in patients with non-small cell lung cancer treated with a combination of tiragolumab and atezolizumab?

What did the phase 2 CITYSCAPE...

09/08/2022

Oncology

Quiz

Quiz: Agradasib-Related Adverse Events in Patients With KRAS-Mutated NSCLC

09/08/2022

According a phase 2 study, what percentage of patients with KRASG12C-mutated NSCLC experienced treatment-related adverse events when treated with adagrasib?

According a phase 2 study, what...

09/08/2022

Oncology

Quiz

Novel MS-VMAT Technique for Whole Lung Irradiation

03/15/2022

At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.

At the 2022 ACRO Annual Meeting,...

03/15/2022

Oncology

Test Your Knowledge

Quiz: Is Lurbinectedin Beneficial for Patients with Pretreated SCLC and Mesothelioma?

12/09/2021

True or false: According to real-world data, lurbinectedin did not demonstrate clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma.

True or false: According to...

12/09/2021

Oncology

Quiz

Quiz: Dose Escalation in Esophageal Cancer

08/15/2021

True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.

True or false: According to...

08/15/2021

Oncology

Test Your Knowledge

Quiz: Pembrolizumab Plus CRT for Locally Advanced NSCLC

08/09/2021

True or false: Pembrolizumab in combination with concurrent chemoradiation therapy offered promising clinical activity in patients with locally advanced non-small cell lung cancer.

True or false: Pembrolizumab in...

08/09/2021

Oncology

Test Your Knowledge

Quiz: Is Pralsetinib Beneficial for RET+ NSCLC?

08/06/2021

True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.

True or false: Oral pralsetinib...

08/06/2021

Oncology

Test Your Knowledge

Quiz: What Combo Therapy Yields Benefit in Patients with EGFR Mutated Advanced NSCLC?

08/03/2021

The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.

The combination of...

08/03/2021

Oncology

Test Your Knowledge

Quiz: Which treatment benefits patients with KRAS p.G12C-mutated non-small cell lung cancer?

07/06/2021

Which treatment showed efficacy and manageable safety in patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer?

Which treatment showed efficacy...

07/06/2021

Oncology

Test Your Knowledge

Quiz: Which Treatment Received FDA Approval for ALK+ NSCLC?

03/23/2021

Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?

Which of the following...

03/23/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology